Fresenius Medical Care North America (FMCNA), a provider of dialysis services, has launched its newly branded Frenova Renal Research business, a phase I-IV drug and device clinical development partner dedicated exclusively to renal research.

Since 2001, Frenova, formerly known as the Clinical Studies Group at FMCNA, has supported sponsors and nephrologists conducting research specific to kidney disease and its comorbid conditions.

“Frenova is a new name, but the company is built on more than a decade of experience focused exclusively on the clinical development of new renal therapies largely developed using the world’s largest dialysis treatment and research network,” said Kurt Mussina, vice president and general manager of Frenova. Frenova provides access to a network comprising more than 390,000 pre-dialysis patients with chronic kidney disease and 183,000 active dialysis patients with end stage renal disease, as well as extensive resources of real-world clinical data collected over the past two decades.

These resources, combined with Frenova’s bioinformatics and analytics capabilities, provide protocol feasibility, optimize research site selection and conduct highly targeted patient recruitment activities.